U.S. AstraZeneca Study Shows Vaccine Gives Total Protection From Severe COVID-19
The findings will now be sent to the Food and Drug Administration to support an emergency authoritzation application.

Reuters/Massimo Pinca
AstraZeneca’s coronavirus vaccine is 100 percent effective in preventing severe disease and hospitalization, according to the results of a long-awaited U.S. trial released early Monday morning. The impressive figures—based on a massive trial which included more than 32,000 participants mostly based in America, but also in Chile and Peru—showed 79 percent efficacy against symptomatic disease and total protection from severe disease. Crucially, the trial identified absolutely no safety concerns and, specifically on the issue of blood clots that caused a wave of panic about the vaccine in some European countries, the independent committee found “no increased risk of thrombosis or events characterized by thrombosis.” The findings will now be sent to the Food and Drug Administration to support an application for emergency authorization of the vaccine.
Register below to read this article for free or subscribe
to unlock unlimited access to The Daily Beast.
Monthly
$1
First month then $5.99/month
Annual
$35
First year then $59.99/year
Premium
$79
First year then $119.99/year
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.
Already have an account? Sign In
Looks like you already have a subscription!
You're all set!
Thanks for subscribing.